Costs and risk factors for ventilator-associated pneumonia in a Turkish University Hospital's Intensive Care Unit: A case-control study

BMC Pulmonary Medicine

Habip Atalay³  Simay Serin³  Mehmet Zencir¹  Ata Nevzat Yalcin²  Riza Hakan Erbay³ 

[1] Department of Public Health, Medicine Faculty, Pamukkale University, Denizli, Turkey;Department of Infectious Diseases and Clinical Microbiology, Medicine Faculty, Akdeniz University, Antalya, Turkey;Department of Anaesthesiology and Reanimation, Medicine Faculty, Pamukkale University, Denizli, Turkey

关键词: cost;    risk factors;    intensive care unit;    ventilator-associated pneumonia;   

Others  :  1172941
DOI  :  10.1186/1471-2466-4-3

 received in 2004-02-06, accepted in 2004-04-26,  发布年份 2004

【 摘 要 】

Background

Ventilator-associated pneumonia (VAP) which is an important part of all nosocomial infections in intensive care unit (ICU) is a serious illness with substantial morbidity and mortality, and increases costs of hospital care. We aimed to evaluate costs and risk factors for VAP in adult ICU.

Methods

This is a-three year retrospective case-control study. The data were collected between 01 January 2000 and 31 December 2002. During the study period, 132 patients were diagnosed as nosocomial pneumonia of 731 adult medical-surgical ICU patients. Of these only 37 VAP patients were assessed, and multiple nosocomially infected patients were excluded from the study. Sixty non-infected ICU patients were chosen as control patients.

Results

Median length of stay in ICU in patients with VAP and without were 8.0 (IQR: 6.5) and 2.5 (IQR: 2.0) days respectively (P < 0.0001). Respiratory failure (OR, 11.8; 95%, CI, 2.2–62.5; P < 0.004), coma in admission (Glasgow coma scale < 9) (OR, 17.2; 95% CI, 2.7–107.7; P < 0.002), depressed consciousness (OR, 8.8; 95% CI, 2.9–62.5; P < 0.02), enteral feeding (OR, 5.3; 95% CI, 1.0–27.3; P = 0.044) and length of stay (OR, 1.3; 95% CI, 1.0–1.7; P < 0.04) were found as important risk factors. Most commonly isolated microorganism was methicillin resistant Staphylococcus aureus (30.4%). Mortality rates were higher in patients with VAP (70.3%) than the control patients (35.5%) (P < 0.003). Mean cost of patients with and without VAP were 2832.2+/-1329.0 and 868.5+/-428.0 US Dollars respectively (P < 0.0001).

Conclusion

Respiratory failure, coma, depressed consciousness, enteral feeding and length of stay are independent risk factors for developing VAP. The cost of VAP is approximately five-fold higher than non-infected patients.

【 授权许可】

   
2004 Erbay et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M: The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995, 274:639-644.
• [2]Legras A, Malvy D, Quinioux AI, Villers D, Bouachour G, Robert R, Thomas R: Nosocomial infections: prospective survey of incidence in five French intensive care units. Intensive Care Med 1998, 24:1040-1046.
• [3]Ponce de Leon-Rosales SP, Molinar-Ramos F, Dominguez-Cherit G, Rangel-Frausto MS, Vazquez-Ramos VG: Prevalence of infections in intensive care units in Mexico: a multicenter study. Crit Care Med 2000, 28:1316-1321.
• [4]Vincent JL: Prevention of nosocomial bacterial pneumonia. Thorax 1999, 54:544-549.
• [5]Lynch JP: Hospital-acquired pneumonia-risk factors, microbiology, and treatment. Chest 2001, 119:S373-S384.
• [6]Mertens R, Van den Berg JM, Veerman-Brenzikofer ML, Kurz X, Jans B, Klazinga N: International comparison of results of infection surveillance: The Netherlands versus Belgium. Infect Control Hosp Epidemiol 1994, 15:574-578.
• [7]Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM: CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16:128-140.
• [8]Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darne C, Gibert C: Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989, 139:877-884.
• [9]Trilla A: Epidemiology of nosocomial infections in adult intensive care units. Intensive Care Med 1994, 20(Suppl 3):S1-4.
• [10]Eggimann P, Pittet D: Infection control in the ICU. Chest 2001, 120:2059-2093.
• [11]Erbay H, Yalcin AN, Serin S, Turgut H, Tomatir E, Cetin B, Zencir M: Nosocomial infections in intensive care unit in a Turkish university hospital: a 2-year survey. Intensive Care Med 2003, 29:1482-1488.
• [12]Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in combined medical-surgical intensive care units in the United States. Infect Control Hosp Epidemiol 2000, 21:510-515.
• [13]Richards MJ, Edwards JR, Culver DH, Gaynes RP: Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999, 27:887-892.
• [14]Kollef MH: Epidemiology and risk factors for nosocomial pneumonia. Emphasis on prevention. Clin Chest Med 1999, 20:653-670.
• [15]Warren DK, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, Cohen MM, Fraser VJ: Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003, 31:1312-1317.
• [16]Rello J, Ollendorf DA, Oster G, Vera-Llonch M, Bellm L, Redman R, Kollef MH: VAP Outcomes Scientific Advisory Group. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122:2115-2121.
• [17]Kollef MH, Sharpless L, Vlasnik J, Pasque C, Murphy D, Fraser VJ: The impact of nosocomial infections on patient outcomes following cardiac surgery. Chest 1997, 112:666-675.
• [18]Mehta RM, Niederman MS: Nosocomial pneumonia. Curr Opin Infect Dis 2002, 15:387-394.
• [19]Tejada Artigas A, Bello Dronda S, Chacon Valles E, Munoz Marco J, Villuendas Uson MC, Figueras P, Suarez FJ, Hernandez A: Risk factors for nosocomial pneumonia in critically ill trauma patients. Crit Care Med 2001, 29:304-309.
• [20]Harris JR, Joshi M, Morton PG, Soeken KL: Risk factors for nosocomial pneumonia in critically ill trauma patients. AACN Clin Issues 2000, 11:198-231.
• [21]Antonelli M, Moro ML, Capelli O, De Blasi RA, D'Errico RR, Conti G, Bufi M, Gasparetto A: Risk factors for early onset pneumonia in trauma patients. Chest 1994, 105:224-228.
• [22]Kampf G, Wischnewski N, Schulgen G, Schumacher M, Daschner F: Prevalence and risk factors for nosocomial lower respiratory tract infections in German hospitals. J Clin Epidemiol 1998, 51:495-502.
• [23]Craven DE, Steger KA: Epidemiology of nosocomial pneumonia. New perspectives on an old disease. Chest 1995, 108(2 Suppl):1S-16S.
• [24]Vincent JL, Lobo S, Struelens M: Ventilator associated pneumonia: risk factors and preventive measures. J Chemother 2001, 13:211-217.
• [25]Vanhems P, Lepape A, Savey A, Jambou P, Fabry J: Nosocomial pulmonary infection by antimicrobial-resistant bacteria of patients hospitalised in intensive care units: risk factors and survival. J Hosp Infect 2000, 45:98-106.
• [26]de Lassence A, Alberti C, Azoulay E, Le Miere E, Cheval C, Vincent F, Cohen Y, Garrouste-Orgeas M, Adrie C, Troche G, Timsit JF, OUTCOMEREA Study Group: Impact of unplanned extubation and reintubation after weaning on nosocomial pneumonia risk in the intensive care unit: a prospective multicenter study. Anesthesiology 2002, 97:148-156.
• [27]Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogue S, Ferrer M: Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999, 27(354):1851-1858.
• [28]Torres A, El-Ebiary M, Rano A: Respiratory infectious complications in the intensive care unit. Clin Chest Med 1999, 20:287-301.
• [29]Akca O, Koltka K, Uzel S, Cakar N, Pembeci K, Sayan MA, Tutuncu AS, Karakas SE, Calangu S, Ozkan T, Esen F, Telci L, Sessler DI, Akpir K: Risk factors for early-onset, ventilator-associated pneumonia in critical care patients: selected multiresistant versus nonresistant bacteria. Anesthesiology 2000, 93:638-645.
• [30]Georges H, Leroy O, Guery B, Alfandari S, Beaucaire G: Predisposing factors for nosocomial pneumonia in patients receiving mechanical ventilation and requiring tracheotomy. Chest 2000, 118:767-774.
• [31]Dalton HJ: Dying from or with a nosocomial pneumonia in the intensive care unit? Crit Care Med 2001, 29:2392-2394.
• [32]Bercault N, Boulain T: Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit Care Med 2001, 29:2303-2309.
• [33]Wilcox MH, Dave J: The cost of hospital-acquired infection and the value of infection control. J Hosp Infect 2000, 45:81-84.
• [34]Yalcin AN: Socioeconomic burden of nosocomial infections. Indian J Med Sci 2003, 57:450-456.
• [35]Public health focus: Surveillance, prevention, and control of nosocomial infections MMWR Morb Mortal Wkly Rep 1992, 41:783-787.
• [36]Jarvis WR: Selected aspects of the socioeconomic impact of nosocomial infections: Morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol 1996, 17:552-557.
• [37]Boyce JM, Potter-Bynoe G, Dziobek L, Solomon SL: Nosocomial pneumonia in Medicare patients. Hospital costs and reimbursement patterns under the prospective payment system. Arch Intern Med 1991, 151:1109-1114.
• [38]Dietrich ES, Demmler M, Schulgen G, Fekec K, Mast O, Pelz K, Daschner FD: Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002, 30:61-67.
• [39]Yalcin AN, Hayran M, Unal S: Economic analysis of nosocomial infections in a Turkish University Hospital. J Chemother 1997, 9:411-414.